Pangenotypic Direct-Acting Antivirals (DAAs) (e.g., Glecaprevir/Pibrentasvir - Mavyret)
Type:
drug
Status:
FDA Approved
Developer:
AbbVie
Breakthrough Summary
No summary available.
Mechanism of Action
Details pending.
Year: 2026